PMID- 16783467
OWN - NLM
STAT- MEDLINE
DCOM- 20070131
LR  - 20220801
IS  - 0271-9142 (Print)
IS  - 0271-9142 (Linking)
VI  - 26
IP  - 3
DP  - 2006 May
TI  - Safety and tolerability of increased rate of infusion of intravenous 
      immunoglobulin G, 10% in antibody-deficient patients.
PG  - 284-90
AB  - The incidence and severity of infusion-related adverse events (AEs) after 
      infusions of IGIV-C, 10%, (Gamunex) at 0.14 mL/kg/min versus 0.08 mL/kg/min 
      (standard rate) were compared. Patients with confirmed PID received two infusions 
      3-4 weeks apart with IGIV-C, 10% 400-600 mg/kg. Patients received their first 
      infusion at 0.08 or 0.14 mL/kg/min and their second infusion 3-4 weeks later at 
      the alternate rate, at an established step-wise rate increase. Ninety-seven of 
      100 patients remained valid for safety assessment. There were three 
      infusion-related reactions at the standard rate and five at the increased rate. 
      The incidence of all reported AEs was similar for both rates. Despite the time 
      required for step-wise increases in infusion rate, the increased rate resulted in 
      a shortened overall infusion time. Increasing the rate of infusion of IGIV-C, 10% 
      by 75% up to 0.14 mL/kg/min (840 mg/kg/h) was well tolerated, suggesting safe 
      administration of IGIV-C, 10% at this rate.
FAU - Gelfand, Erwin W
AU  - Gelfand EW
AD  - National Jewish Medical and Research Center, Denver, Colorado 80206, USA. 
      gelfande@njc.org
FAU - Hanna, Kim
AU  - Hanna K
CN  - IGIV-C Increased Maximum Infusion Rate Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20060531
PL  - Netherlands
TA  - J Clin Immunol
JT  - Journal of clinical immunology
JID - 8102137
RN  - 0 (Caprylates)
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Caprylates/*administration & dosage/adverse effects
MH  - Cross-Over Studies
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/adverse effects
MH  - Immunologic Deficiency Syndromes/*drug therapy
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Single-Blind Method
EDAT- 2006/06/20 09:00
MHDA- 2007/02/01 09:00
CRDT- 2006/06/20 09:00
PHST- 2005/11/07 00:00 [received]
PHST- 2006/01/27 00:00 [accepted]
PHST- 2006/06/20 09:00 [pubmed]
PHST- 2007/02/01 09:00 [medline]
PHST- 2006/06/20 09:00 [entrez]
AID - 10.1007/s10875-006-9014-6 [doi]
PST - ppublish
SO  - J Clin Immunol. 2006 May;26(3):284-90. doi: 10.1007/s10875-006-9014-6. Epub 2006 
      May 31.